L-MYC gene polymorphism and risk of thyroid cancer
L-myc gene polymorphism is a representative genetic trait responsible for an individual’s susceptibility to several cancers. However, there have been no reports concerning the association between thyroid cancer and L-myc gene polymorphism. Aim: To analyze the distribution of L-myc gene polymorphism...
Збережено в:
| Опубліковано в: : | Experimental Oncology |
|---|---|
| Дата: | 2008 |
| Автори: | , , , , , , , , , |
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2008
|
| Теми: | |
| Онлайн доступ: | https://nasplib.isofts.kiev.ua/handle/123456789/139214 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Цитувати: | L-myc gene polymorphism and risk of thyroid cancer / İ. Yaylim-Eraltan, N. Bozkurt, A. Ergen, Ü. Zeybek, O. Öztürk, S. Arıkan, Y. Erbil, İ. Uslu, H. Çamlıca, T. İsbir // Experimental Oncology. — 2008. — Т. 30, № 2. — С. 117-120. — Бібліогр.: 25 назв. — англ. |
Репозитарії
Digital Library of Periodicals of National Academy of Sciences of Ukraine| id |
nasplib_isofts_kiev_ua-123456789-139214 |
|---|---|
| record_format |
dspace |
| spelling |
Yaylim-Eraltan, İ. Bozkurt, N. Ergen, A. Zeybek, Ü. Öztürk, O. Arıkan, S. Erbil, Y. Uslu, İ. Çamlıca, H. İsbir, T. 2018-06-19T20:19:36Z 2018-06-19T20:19:36Z 2008 L-myc gene polymorphism and risk of thyroid cancer / İ. Yaylim-Eraltan, N. Bozkurt, A. Ergen, Ü. Zeybek, O. Öztürk, S. Arıkan, Y. Erbil, İ. Uslu, H. Çamlıca, T. İsbir // Experimental Oncology. — 2008. — Т. 30, № 2. — С. 117-120. — Бібліогр.: 25 назв. — англ. 1812-9269 https://nasplib.isofts.kiev.ua/handle/123456789/139214 L-myc gene polymorphism is a representative genetic trait responsible for an individual’s susceptibility to several cancers. However, there have been no reports concerning the association between thyroid cancer and L-myc gene polymorphism. Aim: To analyze the distribution of L-myc gene polymorphism in Turkish patients with thyroid disorders and thyroid cancers. Methods: We used a molecular genotyping method, polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP). We studied 138 patients of whom 47 had multinodular goiter, 13 had follicular cancer and 69 had papillar cancer, in comparison with control group of 109 healthy individuals. Results: No significant difference in the distribution of genotypes was observed between thyroid patients and controls. Carrying SS or LS genotype revealed a 1.96-fold (95% CI 0.573–6.706) risk for the occurrence of follicular cancer when compared with controls, and 3.11-fold (95% CI 0.952–10.216), when compared with multinodular goiter patients (p = 0.04). Conclusion: We suggest that L-myc genotype profiling together with other susceptibility factors, may be useful in the screening for thyroid nodular malignancy. Для ряда опухолей человека показана корреляция между риском развития опухоли и определенным вариантом гена L-MYC. Данные о наличии такой связи при раке щитовидной железы к настоящему времени отсутствуют. Цель: проанализировать распределение полиморфных типов гена L-MYC в популяции больных с доброкачественными и злокачественными поражениями щитовидной железы, включая рак щитовидной железы, в Турции. Методы: для анализа полиморфизма гена L-MYC использован метод молекулярного генотипирования, в частности, метод определения полиморфизма длины рестрикционных фрагментов, основанный на полимеразной цепной реакции (PCR-RFLP). Определение проводили в лейкоцитах 138 больных, в том числе 48 больных с узловым зобом, 13 больных фолликулярным раком щитовидной железы и 69 больных папиллярным раком. Контрольную группу составляли 109 здоровых лиц. Результаты: статистически достоверных различий в распределении исследуемых генотипов у больных с патологией щитовидной железы и здоровых лиц не выявили. Показано, что относительный риск фолликулярного рака щитовидной железы у больных-носителей генотипа SS или LS составляет 1,96 по сравнению со здоровыми лицами (при 95% доверительном интервале от 0,573 до 6,706) и 3,11 по сравнению с больными с узловым зобом (при 95% доверительном интервале от 0,952 до 10,216) (р = 0,04). Выводы: по нашему предположению, определение профиля полиморфизма гена L-MYC с учетом других факторов, определяющих предрасположенность к развитию опухолей, может быть полезным при скрининге озлокачествления узелковых образований щитовидной железы. This study was supported by a grant from TUBITAK project (101SO11/SBAG 2412). en Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України Experimental Oncology Uncategorized L-MYC gene polymorphism and risk of thyroid cancer Полиморфизм гена L-MYC и риск развития рака щитовидной железы Article published earlier |
| institution |
Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| collection |
DSpace DC |
| title |
L-MYC gene polymorphism and risk of thyroid cancer |
| spellingShingle |
L-MYC gene polymorphism and risk of thyroid cancer Yaylim-Eraltan, İ. Bozkurt, N. Ergen, A. Zeybek, Ü. Öztürk, O. Arıkan, S. Erbil, Y. Uslu, İ. Çamlıca, H. İsbir, T. Uncategorized |
| title_short |
L-MYC gene polymorphism and risk of thyroid cancer |
| title_full |
L-MYC gene polymorphism and risk of thyroid cancer |
| title_fullStr |
L-MYC gene polymorphism and risk of thyroid cancer |
| title_full_unstemmed |
L-MYC gene polymorphism and risk of thyroid cancer |
| title_sort |
l-myc gene polymorphism and risk of thyroid cancer |
| author |
Yaylim-Eraltan, İ. Bozkurt, N. Ergen, A. Zeybek, Ü. Öztürk, O. Arıkan, S. Erbil, Y. Uslu, İ. Çamlıca, H. İsbir, T. |
| author_facet |
Yaylim-Eraltan, İ. Bozkurt, N. Ergen, A. Zeybek, Ü. Öztürk, O. Arıkan, S. Erbil, Y. Uslu, İ. Çamlıca, H. İsbir, T. |
| topic |
Uncategorized |
| topic_facet |
Uncategorized |
| publishDate |
2008 |
| language |
English |
| container_title |
Experimental Oncology |
| publisher |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| format |
Article |
| title_alt |
Полиморфизм гена L-MYC и риск развития рака щитовидной железы |
| description |
L-myc gene polymorphism is a representative genetic trait responsible for an individual’s susceptibility to several cancers. However, there have been no reports concerning the association between thyroid cancer and L-myc gene polymorphism. Aim: To analyze the distribution of L-myc gene polymorphism in Turkish patients with thyroid disorders and thyroid cancers. Methods: We used a molecular genotyping method, polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP). We studied 138 patients of whom 47 had multinodular goiter, 13 had follicular cancer and 69 had papillar cancer, in comparison with control group of 109 healthy individuals. Results: No significant difference in the distribution of genotypes was observed between thyroid patients and controls. Carrying SS or LS genotype revealed a 1.96-fold (95% CI 0.573–6.706) risk for the occurrence of follicular cancer when compared with controls, and 3.11-fold (95% CI 0.952–10.216), when compared with multinodular goiter patients (p = 0.04). Conclusion: We suggest that L-myc genotype profiling together with other susceptibility factors, may be useful in the screening for thyroid nodular malignancy.
Для ряда опухолей человека показана корреляция между риском развития опухоли и определенным вариантом гена L-MYC.
Данные о наличии такой связи при раке щитовидной железы к настоящему времени отсутствуют. Цель: проанализировать
распределение полиморфных типов гена L-MYC в популяции больных с доброкачественными и злокачественными
поражениями щитовидной железы, включая рак щитовидной железы, в Турции. Методы: для анализа полиморфизма
гена L-MYC использован метод молекулярного генотипирования, в частности, метод определения полиморфизма длины
рестрикционных фрагментов, основанный на полимеразной цепной реакции (PCR-RFLP). Определение проводили в
лейкоцитах 138 больных, в том числе 48 больных с узловым зобом, 13 больных фолликулярным раком щитовидной железы
и 69 больных папиллярным раком. Контрольную группу составляли 109 здоровых лиц. Результаты: статистически
достоверных различий в распределении исследуемых генотипов у больных с патологией щитовидной железы и здоровых
лиц не выявили. Показано, что относительный риск фолликулярного рака щитовидной железы у больных-носителей
генотипа SS или LS составляет 1,96 по сравнению со здоровыми лицами (при 95% доверительном интервале от 0,573
до 6,706) и 3,11 по сравнению с больными с узловым зобом (при 95% доверительном интервале от 0,952 до 10,216) (р =
0,04). Выводы: по нашему предположению, определение профиля полиморфизма гена L-MYC с учетом других факторов,
определяющих предрасположенность к развитию опухолей, может быть полезным при скрининге озлокачествления узелковых
образований щитовидной железы.
|
| issn |
1812-9269 |
| url |
https://nasplib.isofts.kiev.ua/handle/123456789/139214 |
| citation_txt |
L-myc gene polymorphism and risk of thyroid cancer / İ. Yaylim-Eraltan, N. Bozkurt, A. Ergen, Ü. Zeybek, O. Öztürk, S. Arıkan, Y. Erbil, İ. Uslu, H. Çamlıca, T. İsbir // Experimental Oncology. — 2008. — Т. 30, № 2. — С. 117-120. — Бібліогр.: 25 назв. — англ. |
| work_keys_str_mv |
AT yaylimeraltani lmycgenepolymorphismandriskofthyroidcancer AT bozkurtn lmycgenepolymorphismandriskofthyroidcancer AT ergena lmycgenepolymorphismandriskofthyroidcancer AT zeybeku lmycgenepolymorphismandriskofthyroidcancer AT ozturko lmycgenepolymorphismandriskofthyroidcancer AT arıkans lmycgenepolymorphismandriskofthyroidcancer AT erbily lmycgenepolymorphismandriskofthyroidcancer AT uslui lmycgenepolymorphismandriskofthyroidcancer AT camlıcah lmycgenepolymorphismandriskofthyroidcancer AT isbirt lmycgenepolymorphismandriskofthyroidcancer AT yaylimeraltani polimorfizmgenalmyciriskrazvitiârakaŝitovidnoiželezy AT bozkurtn polimorfizmgenalmyciriskrazvitiârakaŝitovidnoiželezy AT ergena polimorfizmgenalmyciriskrazvitiârakaŝitovidnoiželezy AT zeybeku polimorfizmgenalmyciriskrazvitiârakaŝitovidnoiželezy AT ozturko polimorfizmgenalmyciriskrazvitiârakaŝitovidnoiželezy AT arıkans polimorfizmgenalmyciriskrazvitiârakaŝitovidnoiželezy AT erbily polimorfizmgenalmyciriskrazvitiârakaŝitovidnoiželezy AT uslui polimorfizmgenalmyciriskrazvitiârakaŝitovidnoiželezy AT camlıcah polimorfizmgenalmyciriskrazvitiârakaŝitovidnoiželezy AT isbirt polimorfizmgenalmyciriskrazvitiârakaŝitovidnoiželezy |
| first_indexed |
2025-11-24T02:35:15Z |
| last_indexed |
2025-11-24T02:35:15Z |
| _version_ |
1850838339148578816 |
| fulltext |
Experimental Oncology ��� �������� ���� ���ne� ������ �������� ���� ���ne� �����ne� ���� ��� ���
L-myc gene belonging to the myc family is an on-
cogene� localized to chromosome �p�4 and tho�ght
to be activated d�ring late t�morigenesis [�� �]. Since
the cloning of L-myc gene in �9�5� enormo�s amo�nt
of research has been cond�cted to help el�cidate the
role of this gene in h�man malignancy [�]. A possible
role of the myc oncogene in the neoplastic transforma-
tion of the h�man thyroid gland has been investigated.
Some researchers s�ggest that myc-oncogene altera-
tions might be involved in malign transformation of the
h�man thyroids [4� 5]. The non-coding variation in
the second intron of the L-myc gene� generating an
EcoRI polymorphism� is associated with increased risk
of seve ral t�mor types� altho�gh controversial res�lts
have been reported [6� �]. Some of the res�lts s�gges-
ted that L-myc gene polymorphism had some infl�ence
on the s�sceptibility to cancer. However� no st�dy on
the relevance of L-myc gene polymorphism to thyroid
carcinogenesis has yet been reported. Identification
of s�sceptibility factors that predispose individ�als to
thyroid cancer co�ld possibly give f�rther insight into
the etiology of this malignancy. In this st�dy� we have
tried to establish a relationship bet ween differentiated
thyroid cancers and L-myc gene polymorphism. With
this aim� we analyzed the L-myc gene stat�s of diffe-
rentiated thyroid cancer patients� m�ltinod�lar goiter
patients and healthy people for a comparison.
MATERIALS AND METHODS
Material. Blood samples from patients operated
for nod�lar �m�ltinod�lar� e�thyroid goiter in Istanb�l
Medical Fac�lty� Haseki Ed�cational Hospital and
Cerrahpaşa Medical Fac�lty in ��������5 were col-
lected and �sed. The st�dy pop�lation consisted of
4� patients with benign thyroid nod�les incl�ding only
goiter patients and �� patients with malignant nod�les�
incl�ding 69 cases of papillary carcinoma �PC� and
�� cases of follic�lar carcinoma �FC�. The diagnosis of
differentiated thyroid carcinoma �papillary and follic�-
lar carcinomas� and m�ltinod�lar goiter patients was
made by the pathological analysis of thyroid specimens
after s�rgery. All patients �nderwent total or s�btotal
�for a few benign goiter patients� thyroidectomy. None
of the patients had a history of accidental or medical
radiation expos�re. Control gro�p incl�ded patients of
the general s�rgery and orthopedic clinics of the same
hospital� which were being treated for non-neoplastic
diseases s�ch as ing�inal hernia or tra�ma. All data�
incl�ding pathological diagnoses� age� gender and
s�rgical findings were recorded. S�bjects reporting
cigarette smoking still in the year prior to examination
were determined. Demographic data of patients and
controls were shown in Table �. Blood samples were
collected from all patients preoperatively and L-myc
gene polymorphism was performed after obtaining
the res�lt of pathological analysis.
Table 1. Demographic data of our study groups
Study groups Males n
(%)
Females n
(%) Total
Mean
age
(years)
Smoking
history (+)
n (%)
Controls 31 (32.6) 64 (67.4) 95 41.2 30 (31.6)
Follicular carcinomas 3 (23.1) 10 (76.9) 13 42.2 2 (15.4)
Papillary carcinomas 19 (27.5) 50 (72.5) 69 34.8 2 (2.9)
Multinodular goiter 9 (19.1) 38 (80.9) 47 40.8 1 (2.1)
Note. n = number of cases.
Isolation of DNA. Blood specimens from all
s�bjects were collected into t�bes containing EDTA.
DNA was isolated from the blood le�kocytes in �� ml
EDTA by the method of Miller et al. based on sodi�m
L-MYC GENE POLYMORPHISM AND RISK OF THYROID CANCER
İ. Yaylim-Eraltan1, N. Bozkurt1, A. Ergen1, Ü. Zeybek1,
O. Öztürk1, S. Arıkan2, Y. Erbil3, İ. Uslu4, H. Çamlıca5, T. İsbir1, *
1Institute of Experimental Medical Research, Department of Molecular Medicine, Istanbul University, Istanbul, Turkey
2Istanbul Research and Education Hospital, Surgery Clinic, Istanbul, Turkey
3Istanbul University, Istanbul Medical Faculty, Department of General Surgery, Istanbul, Turkey
4Istanbul University, Cerrahpasa Medical Faculty, Department of Nuclear Medicine, Istanbul, Turkey
5Istanbul University, Institute of Oncology, Division of Cancer Epidemiology and Biostatistics, Istanbul, Turkey
L-myc gene polymorphism is a representative genetic trait responsible for an individual’s susceptibility to several cancers. However, there
have been no reports concerning the association between thyroid cancer and L-myc gene polymorphism. Aim: To analyze the distribution
of L-myc gene polymorphism in Turkish patients with thyroid disorders and thyroid cancers. Methods: We used a molecular genotyping
method, polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP). We studied 138 patients of whom 47
had multinodular goiter, 13 had follicular cancer and 69 had papillar cancer, in comparison with control group of 109 healthy individuals.
Results: No significant difference in the distribution of genotypes was observed between thyroid patients and controls. Carrying SS or
LS genotype revealed a 1.96-fold (95% CI 0.573–6.706) risk for the occurrence of follicular cancer when compared with controls, and
3.11-fold (95% CI 0.952–10.216), when compared with multinodular goiter patients (p = 0.04). Conclusion: We suggest that L-myc
genotype profiling together with other susceptibility factors, may be useful in the screening for thyroid nodular malignancy.
Key Words: allele, cancer, L-myc, polymorphism, thyroid gland.
Received: July 26, 2007.
*Correspondence: Fax: +90 212 635 19 59
E-mail: tisbir@superonline.com
Abbreviations used: FC – follicular carcinoma; PC – papillary car-
cinoma; PCR-RFLP – polymerase chain reaction-based restriction
fragment length polymorphism
Exp Oncol ����
��� �� �������
��� Experimental Oncology ��� �������� ���� ���ne�
dodecyl s�lphate lysis� ammoni�m acetate extraction
and ethanol precipitation [�].
Polymerase Chain Reaction (PCR) for L-myc
Oncogene. Template DNA ��.5��.� µg� was �sed
in a PCR �nder sterile conditions. ��� ng of primer
was �sed for the reaction — the forward primer was
5’-AGT-TCA-CTC-ACA-GGC-CAC-AT-�’ and the
reverse primer was 5’-TGC-ATA-TCA-GGA-AGC-TTG-
AG-�’ in a vol�me of 5� µl containing � mM MgCl��
5� mM KCl ��� mM Tris HCl �pH �.4� �.5 mM of each
dNTP �MBI Fermentas� and � �nit of Taq DNA Poly-
merase �MBI Fermentas�. Amplification was performed
in a DNA thermal cycler �MBI Fermentas�for �� cycles
with denat�ration steps at 94 °C for �� s� annealing
at 5� °C for � min and extension at �4 °C for � min.
The PCR prod�ct exhibited a �6� base pair fragment.
Amplification fragment was digested with 5 �nits EcoRI
�MBI Fermentas� at �� °C for � h [9]. The digested DNA
fragments were separated by gel electrophoresis on
a �% agarose gel in � x Tris Borate EDTA b�ffer and
DNA vis�alized by ethidi�m bromide staining. The re-
sponsible L-myc RFLP alleles were identified in each
sample .The three genotypes were the LL homozygote
appearing as �6�-base pair �bp� fragment� the LS
heterozygote with �6�� �4�� and ��5-bp fragments
and the SS homozygote with �4� and ��5-base pair
fragments �Fig�re�.
– 267 bp
– 142 bp
– 125 bp
50 bp
marker LL LS LL LS SS
Figure. Direct vis�alization of PCR prod�cts by ethidi�m bro-
mide staining. A �6�-base pair L-myc fragment was amplified�
cleaved with Eco RI and electrophoresed on a �% agarose gel.
Res�lts for five representative tyroid cancer patients are shown.
Molec�lar weight markers are at the left and the �nc�t �6� base
pair L-allele� and �4� and ��5 base pair S allele are designated
at the right
Statistical Analysis. Statistical analyses were
performed �sing the SPSS version �.5 incl�ding the
Chi Sq�are �χ�� test and Yate’s correction for genotype
and allele freq�encies composition. Odds ratios and
95% confidence intervals were calc�lated for all three
genotypes.
RESULTS
The n�mber of females was higher in o�r thyroid
patients than in control gro�ps. However� we were not
able to find any possible correlation between genotype
and possible risk factors like age� gender and smo-
king habit. Histologic classification of thyroid t�mors
was as follows: 5�.5% papillary t�mors �69 patients��
��.�% follic�lar t�mors ��� patients�� �6.4% m�lti-
nod�lar goiter �4� patients�. Table � s�mmarizes the
data of the overall proportion of the L-myc genotypes
in control pop�lation and in patients with benign and
malignant thyroid diseases.
Table 2. Comparison between the different L-myc genotypes in the control
population and in the benign and malignant thyroid disease patients
Genotypes Controls,
n (%)
Multinodular
goiter, n (%)
Papillar
cancer, n (%)
Follicular
cancer, n (%)
LL 37 (38.9%) 24 (51.1%) 28 (40.6%) 3 (23.1%)
LS 47 (49.5%) 15 (31.9%) 30 (43.5%) 10 (76.9%)
SS 11 (11.6%) 8 (17.01%) 11 (15.9%) 0 (0%)
Total of cases 95 47 69 13
LL 37 (38.9% ) 26 ( 55.3% ) 28 ( 40.6% ) 3 (23.1% )
LS + SS 58 (61.1%) 21 (44.7%) 41 (59.4%) 10 (76.9%)
Note. n = number of cases.
There was no statistically significant difference
fo�nd between vario�s types of thyroid disorders in
regard to L-myc gene polymorphism expect in allele
freq�encies among patients with benign and malign
nod�les. The L-myc S allele tended to be more fre-
q�ent among the follic�lar thyroid cancer patients
�freq�ency �6.9%� than among controls �6�.�%� b�t
witho�t reaching a significant level. In o�r follic�lar
thyroid cancer patients� the freq�ency of L-myc S allele
was higher than it was in m�ltinod�lar goiter patients
and the difference is statistically significant �χ� = 4.���
p = �.�4�. Patients with S allele �SS or LS genotypes�
showed a �.96-fold �95% CI �.5���6.��6� risk for fol-
lic�lar thyroid cancer when compared with controls�
and �.��-fold �95% CI �.95����.��6; p = �.�4� when
compared with m�ltinod�lar goiter patients.
DISCUSSION
L-myc is one of the three major members of the
myc proto-oncogene family. These genes encode
proteins that play distinct b�t overlapping roles in a
wide range of normal and aberrant cell�lar processes
incl�ding cell proliferation� differentiation� apoptosis
and t�morigenesis [��� ��]. L-myc has been m�ch less
intensively st�died than the other two members of the
myc gene family� c-myc or N-myc. No previo�s st�dies
have reported genetic polymorphism of L-myc gene
associated with thyroid carcinomas. It is known that
m�tations of genes involved in the control of cell�lar
growth and/or differentiation� s�ch as c-myc� affect
the development of thyroid neoplasms [4� 5]. The
freq�ency of females was significantly higher in the
st�dy pop�lation� as well as in the gro�ps of papillary
and follic�lar cancer� which is in agreement with the
gender distrib�tion �s�ally observed in this type of
cancers [��]. B�rman et al. showed that c-myc onco-
gene expression is comparable in normal thyrocytes
and in thyroid nod�les or thyroid cancer samples [��].
Those findings s�pport a role for c-myc in both nor-
mal and neoplastic thyrocyte growth. On the other
Experimental Oncology ��� �������� ���� ���ne� ��9��� �������� ���� ���ne� ��9��ne� ��9� ��9 ��9
hand� a st�dy by Bieche et al. reported that none of
the neoplastic thyroid samples overexpressed myc
oncogene [�4].
The L-myc EcoRI polymorphism is a non-coding
variation in the second intron of the L-myc gene res�l-
ting in S and L alleles. Individ�als carrying the S allele
tend to have poor prognosis and increased risk of
seve ral t�mor types� altho�gh controversial res�lts
have been reported [6]. Since the first st�dy of the
L-myc RFLP in �apanese l�ng cancer patients reported
in �9��� many researchers have st�died the L-myc
RFLP types in different cases of l�ng cancer and other
malignant t�mors. Some of these st�dies have shown
a positive relationship between L-myc genotypes and
s�sceptibility to some types of cancer [�5���]� b�t other
st�dies fo�nd no relationship between L-myc genotypes
and s�sceptibility to the same and other types of can-
cer [�� ��]. These res�lts s�ggest that f�rther st�dies
are req�ired to clarify the relationship between L-myc
genotypes and s�sceptibility to cancer [�9]. The present
st�dy indicated that there was no significant difference
in the distrib�tion of L-myc RFLP between patients with
thyroid cancer and control gro�p. The only positive find-
ing observed was for follic�lar thyroid cancer patients
classified into two genotype gro�ps “LS type pl�s SS
genotype” and “LL genotype”� where the “LS pl�s SS
genotype” gro�p� which showed a higher val�e of rela-
tive risk� was tho�ght to be a higher risk gro�p compared
with the “LL genotype” gro�p. We showed that having
S allele �SS or LS genotype� ca�sed a �.96-fold risk of
follic�lar thyroid cancer when compared with controls�
which was �.��-fold risk on comparison with m�ltinod�-
lar goiter patients.
Altho�gh clinical and epidemiological feat�res are
helpf�l� there are still no accepted serological markers
that can help identify patients at risk for malignancy
among individ�als with thyroid nod�les [��� ��]. The
association of L-myc gene polymorphism with cancer
s�sceptibility has prod�ced conflicting res�lts. This
may have been d�e to racial/ethnic differences and
methodological variations in the st�dies� s�ch as
control selection and case stratification [��]. In o�r
female patients� papillary and follic�lar carcinomas
were two to fo�r times more freq�ent than men� as
s�pported by the previo�s literat�re [��]� partic�larly
in reprod�ctive years. This has lead to the hypothesis
that female hormones or X chromosomal genes might
be involved in the etiology or pathogenesis of the
disease [��]. This hypothesis is s�pported by data of
molec�lar genetic analysis of thyroid cancers� which
also s�ggest the existence of different molec�lar
mechanisms leading to papillary and follic�lar thy-
roid cancers [�4� �5]. Papillary and follic�lar t�mors
sho�ld be examined separately for the identification of
p�tative risk genotypes for thyroid cancer. Conversely�
when considered alone� polymorphic L-myc gene is
not strongly associated with thyroid cancer� as has
been observed for other types of cancer. We s�ggest
that L-myc genotype profiling together with other
s�sceptibility factors� may be �sef�l in the screening
for thyroid nod�le malignancy.
ACKNOwLEDGEMENTS
This st�dy was s�pported by a grant from TUBITAK
project ����SO��/SBAG �4���.
REFERENCES
1. Shiraishi M, Noguchi M, Shimosato Y, Sekiya T. Am-
plification of protooncogenes in surgical specimens of human
lung carcinomas. Cancer Res 1989; 49: 6474–9.
2. Speleman F, Van Camp G, Van Roy N. Reassignment of
MYCL1 to human chromosome 1p34.3 by fluorescence in situ
hybridization. Cytogenet Cell Genet 1996; 72: 189–90.
3. Nau MM, Brooks BJ, Battey J, et al. L-myc, a new
myc-related gene amplified and expressed in human small cell
lung cancer. Nature 1985; 318: 69–73.
4. del Senno L, Gambari R, Uberti E, et al. C-myc onco-
gene alterations in human thyroid carcinomas. Cancer Detect
Prev 1987; 10: 159–66.
5. Ferenc T, Maciaszczyk K, Gesing A, Lewinski A. The
role of genetic factors in he pathogenesis of thyroid neoplasms.
Postepy Hig Med Dosw 1997; 51: 367–84.
6. Spinola M, Pedotti P, Dragani TA, Taioli E. Meta-
analysis suggests association of L-myc Eco RI polymorphism
with cancer prognosis Clin Cancer Res 2004; 10: 4769–75.
7. Togo AV, Suspitsin EN, Grigoriev MY, et al. L-myc
polymorphism in cancer patients, healthy blood donors. Int J
Cancer 2000; 85: 747–50.
8. Miller SA, Dykes DD, Polesky HS. Simples salting out
procedure for extracting DNA from human nucleated cells.
Nucleic Acid Research 1988; 16: 1215–9.
9. Tamai S, Sugimura H, Caporaso NE, et al. Restriction
fragment length polymorphism analysis of the L-myc gene
locus in a case control study of lung cancer. Int J Cancer
1990; 46: 411–5.
10. Grandori C, Cowley SM, James LP, Eisenman RN. The
myc/max/mad network and the transcriptional control of cell
behaviour. Ann Rev Cell Dev Biol 2000; 16: 653–99.
11. Morgenbesser SD, Schreiber- Agus N, Bidder M, et al.
Contrasting roles for-c-myc and L-myc in the regulation of
cellular growth and differentiation in vivo. EMBO J 1995; 14:
753–6.
12. Schlumberger MJ. Papillary and follicular tyhroid
carcinoma. N Engl J Med 1998; 338: 297–306.
13. Burman KD, Djuh YY, La Rocca RV, et al. C-myc ex-
pression in the thyroid I: normal adenomatous, and cancerous
thyroid tissue. Horm Metab Res 1987; 17 (Suppl): 63–5.
14. Bieche I, Franc B, Vidaud D, et al. Analyses of myc,
ErbB 2, and CCND1 genes in benign and malignant thyroid
follicular cell tumors by real-time polymerase chain reaction.
Thyroid 2001; 11: 147–52.
15. Shibuta K, Mori M, Haraguchi M, et al. Association
between restriction fragment length polymorphism of the
L-myc gene and susceptibility to gastric cancer. Br J Cancer
1998; 85: 681–4.
16. Kato M, Toguchida J, Honda K, et al. Elevated frequency
of a specific allele of the L-myc gene in male patients with bone
and soft-tissue sarcomas. Int J Cancer 1990; 45: 47–9.
17. Shibuta K, Inoue H, Sato K, et al. L-myc restriction
fragment length polymorphism in Japanese patients with
esophageal cancer. Jpn J Cancer Res 2000; 91: 199–203.
18. Ejarque MJ, Vicente M, Bernves M, et al. Restriction
fragment length polymorphism of the L-myc gene is not a
prognostic factor in bladder cancer patients. Br J Cancer 1999;
79: 1855–8.
��� Experimental Oncology ��� �������� ���� ���ne�
19. Kumimoto H, Hamojima N, Nishizawa K, et al. Diffe-
rent susceptibility of each L-myc genotype to esophageal
cancer risk factors. Jpn J Cancer Res 2001; 92: 735–9.
20. Vineis P. Cancer as an evolutionary process at the cell
level: An epidemiological perspective. Carcinogenesis 2003;
24: 1–6.
21. Schlumberger MJ, Torlantano M. Papillary and
follicular thyroid carcinoma. Ballieres Best Pract Res Clin
Endometab 2000; 14: 601–3.
22. Chenevix-Trench G, Southall M, Kidson C. Restriction-
fragment length polymorphisms of L-myc and myb in human
leukaemia and lymphoma in relation to age-selected controls.
Br J Cancer 1989; 60: 872–4.
23. Rossing M, Voigt L, Wicklund K, et al. Use of exogenous
hormones and the risk of papillary thyroid cancer (Washington,
United States). Cancer Causes Control 1998; 9: 941–9.
24. Zou M, Shi Y, Farid N, et al. FHIT gene abnormalities
in both benign and malignant thyroid tumors. Eur J Cancer
1999; 35: 467–72.
25. Gaspar J, Rodrigues S, Gil OM, et al. Combined effects
of glutathione S transferase polymorphisms and thyroid cancer
risk. Cancer Gen Cytogen 2004; 151: 60–7.
ПОЛИМОРФИЗМ ГЕНА L-MYC И РИСК РАЗВИТИЯ РАКА
ЩИТОВИДНОЙ ЖЕЛЕЗЫ
Для ряда опухолей человека показана корреляция между риском развития опухоли и определенным вариантом гена L-MYC.
Данные о наличии такой связи при раке щитовидной железы к настоящему времени отсутствуют. Цель: проанализиро-
вать распределение полиморфных типов гена L-MYC в популяции больных с доброкачественными и злокачественными
поражениями щитовидной железы, включая рак щитовидной железы, в Турции. Методы: для анализа полиморфизма
гена L-MYC использован метод молекулярного генотипирования, в частности, метод определения полиморфизма длины
рестрикционных фрагментов, основанный на полимеразной цепной реакции (PCR-RFLP). Определение проводили в
лейкоцитах 138 больных, в том числе 48 больных с узловым зобом, 13 больных фолликулярным раком щитовидной же-
лезы и 69 больных папиллярным раком. Контрольную группу составляли 109 здоровых лиц. Результаты: статистически
достоверных различий в распределении исследуемых генотипов у больных с патологией щитовидной железы и здоровых
лиц не выявили. Показано, что относительный риск фолликулярного рака щитовидной железы у больных-носителей
генотипа SS или LS составляет 1,96 по сравнению со здоровыми лицами (при 95% доверительном интервале от 0,573
до 6,706) и 3,11 по сравнению с больными с узловым зобом (при 95% доверительном интервале от 0,952 до 10,216) (р =
0,04). Выводы: по нашему предположению, определение профиля полиморфизма гена L-MYC с учетом других факторов,
определяющих предрасположенность к развитию опухолей, может быть полезным при скрининге озлокачествления узел-
ковых образований щитовидной железы.
Ключевые слова: аллель, рак, L-myc, полиморфизм, щитовидная железа.
Copyright © Experimental Oncology, 2008
|